New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 9, 2014
16:12 EDTRCPTReceptos says Phase 2 study of RPC1063 met primary efficacy endpoint
Receptos announced that the Phase 2 portion of the RADIANCE trial of its selective S1P1 receptor modulator, RPC1063, in relapsing multiple sclerosis met the primary endpoint, reduction in MRI brain lesion activity. The overall safety profile of RPC1063 was consistent with the results of prior trials, and continues to support the differentiation of the drug candidate against other oral agents for treatment of RMS on the market or in clinical development.
News For RCPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 31, 2014
09:53 EDTRCPTReceptos management to meet with Leerink
Subscribe for More Information
October 28, 2014
12:57 EDTRCPTOn The Fly: Midday Wrap
Subscribe for More Information
10:40 EDTRCPTHigh option volume stocks
Subscribe for More Information
09:20 EDTRCPTOn The Fly: Pre-market Movers
Subscribe for More Information
08:47 EDTRCPTReceptos price target raised to $125 from $72 at BMO Capital
Subscribe for More Information
08:13 EDTRCPTReceptos price target raised to $112 from $77 at Leerink
Subscribe for More Information
07:08 EDTRCPTReceptos price target raised to $153 from $80 at Wedbush
Wedbush raised Recptos' price target to $153 following strong Ulcerative Colitis results.
October 27, 2014
18:26 EDTRCPTOn The Fly: After Hours Movers
Subscribe for More Information
16:08 EDTRCPTReceptos up 32.7% after RPC1063 Phase 2 trial met primary, secondary endpoints
16:07 EDTRCPTReceptos reports RPC1063 Phase 2 trial met primary, all secondary endpoints
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use